BMO Capital Upgrades Regeneron Pharma (REGN) to Outperform
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $759.24 --0%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 18 | New: 19
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 18 | New: 19
Join SI Premium – FREE
BMO Capital upgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Outperform with a price target of $158.00 (from $143.00).
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Palantir (PLTR) to Buy, 'risk/reward skews favorably'
- Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform
- Regeneron Pharma (REGN) PT Raised to $761 at Baird
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
